daftar pustakaeprints.undip.ac.id/71112/9/daftar_pustaka_dan_lampiran.pdfhasbullah b. angka kejadian...
TRANSCRIPT
86
DAFTAR PUSTAKA
1. Jarvis TR, Chughtai B, Kaplan SA. Bladder Outlet Obstruction and BPH.
Current Bladder Dysfunction Reports.2014;9(4):372
2. Patel ND, Parsons JK. Epidemiology and Etiology of Benign Prostatic
Hyperplasia and Bladder Outlet Obstruction. Indian J Urol.2014;30(2):170-
6
3. Sarma AV, Wei JT. Benign prostate hyperplasia and lower urinary tract
symptomp. NEJM 2012. 367 : 248-57
4. Fadlol A, Mochtar CA. Prediksi Volume Prostat pada Penderita Pembesaran
Prostat Jinak. JIBI.2005;33(4):139-45
5. Kurniawati DH. Profil komplikasi pada pasien hiperplasi prostat jinak paska
tindakan TURP di RS DR Sardjito Jogjakarta. Fakultas Kedokteran
Universitas Gajah mada; 2004.
6. Hasbullah B. Angka Kejadian Komplikasi Lambat Pascaoperasi
Prostatektomi Transvesikal dan Reseksi Transuretral pada Pasien
Pembesaran Prostat Jinak. Jurnal Biomedika 2009 1 : 1-5
7. Rachmat BP, Soetojo. Perbedaan kadar PSA dan TGF β-1 terhadap
pemberian kombinasi 5α reduktase inhibitor (dutasteride) dan anti estrogen
(tamoxifen) pada penderita BPH-LUTS. Fakultas Kedokteran Unair
Surabaya; 2006.
8. Lynch M, SriprasadS, Subramonian S, Thompson P. Postoperative
haemorrhage following transurethral resection of the prostate (TURP) and
photoselective vaporisation of the prostate (PVP), Ann R Coll Surg Engl
2010; 92: 555–8
9. Shanmugasundaram R, Singh JC, Kekre NS. Does dutasteride reduce
perioperative blood loss and postoperative complications after transurethral
resection of the prostate?. Uroscan, 23(3) : 334-5
10. Walsh PC, Retik AB. Transurethral surgery.In : Campbell’s urology 7th ed.
WB saunders. Philadelphia, 1998 : 1511-28.
87
11. Foley CL, Bott SR, Kirby RS. An update on the 5 alpha reductase inhibitor.
Timely Top Med Urol 2003 vol 4, Jun 2003
12. Robert G Hahn, Tim Fagerstrom.Blood loss and postoperative complications
associated with transurethral resection of the prostate after pretreatment with
dutasteride. BJU Int 2007. 99 : 587-94
13. Chapple CR. Pharmacological therapy of benign prostatic/lower urinary
tract symptoms:an overview for the practicing clinician. BJU Int 2004 vol 94
: 738-44
14. Andriole G, Bruchovsky N, et al. Dihydrotestosterone and the prostate: The
scientific rationale for 5 α reductase inhibitors in the treatment of benign
prostatic hyperplasia. The Journal of Urol. Vol 172, Oct 2004 : 1399-403
15. Schwarz S, Obermuller-Jevic C Ute, Hellmis Eva, Koch Winfried, Jacobi
Gunther, Biesalaskin Hans-Konrad. Lycopene Inhibits Disease Progression
in Patient with Benign Prostate Hyperplasia. J Nut,2008,138:53-49
16. Rao AV, Agarwal S. Role of Antioxidant Lycopene in Cancer and Heart
Disease. American College of Nutrition. 2002;Vol.19:5;569-3
17. McCance L. Kathryn, Huether. E Sue. The Biology Basic for Disease in
Adults and Children. 2014
18. Barry MJ, Fowler FJ, Bin L, Pitts JC, Harris CJ, Mulley AG. The Natural
History of Patients with Benign Prostatic Hyperplasia as Diagnosed by North
American Urologists. J Urol.1997;157(1):10-4
19. Amalia R. Faktor-Faktor Risiko Terjadinya Pembesaran Prostat Jinak (Studi
kasus di RS dr. Kariadi, RS Roemani dan RSI Sultan Agung Semarang). Tesis
Program Studi Magister Epidemiologi, Program Pasca Sarjana Universitas
Diponegoro; Semarang; 2007. Downloaded from
http://eprints.undip.ac.id/19133/1/Rizki_Amalia.pdf
20. Data Base Sub-Bagian Urologi, SMF Bedah RS Dr. Kariadi, Semarang, 2015
21. Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological
Association and European Association of urology guidelines in the
management of benign prostatic hypertrophy.Curr Opin Urol. 2012
Jan;22(1):34-9
88
22. Presti JC. Neoplasm of the prostat gland. In : Tanagho EA, Mc Aninch JW
eds. Smith’s general urology 15th ed. Lange Medical Books/Mc Graw Hill.
New York. 2000 : 399-417
23. Healey JE, Hodge J. Surgical anatomy 2nd ed. B.C. Decker Inc. Philadelphia.
1990 : 216.
24. Carmeliet P, Jain RK. Review article Angiogenesis in cancer and other
disease. Nature.2000;40(6810):249-57
25. Risau W. Mechanism of angiogenesis. Nature 1997;386:671-4
26. Yancopoulos GD, David S, Gale NW, et al. Vascular-spesific growth factors
and blood vessel formation. Nature 2000;407:242-8
27. Rosen LS. Clinical experience with angiogenesis signaling inhibitors : focus
on vascular endothelial growth factor (VEGF) blockers. Cancer Control
2002, 9(2) : 36-44
28. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway
in tumor growth and angiogenesis. Journal of Clinical Oncology. 2005; 23(5)
: 1011-12
29. Haris AL. Angiogenesis for cancer therapy. Lancet 1997, 349,13-5
30. Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in
prostatic disease, BJU Inter, 1999,84 : 1081-3
31. Pareek G, Shevchuck M, Armenakas NA, Vasjovic L, Hochberg DA,
Bassilote JB, Fracchia JA. The effect of finasteride on the expression of
vascular endothelial growth factor and microvessel density. A possible
mechanism for decreased prostatic bleeding in treated patients, J Urol, 2003,
169 :20-3
32. Chang YS, di Tomaso E, Mc Donald DM et al. Mosaic blood vessel in tumors
: frequency of cancer cells in contact with flowing blood. Proc Natl Acad USA
2000;97 :14608-13
33. Dvorak HF. Tumors : wound that do not heal. Similarities between tumor
stroma generation and wound healing. N Eng J Med 1986;315 : 1650-9
34. Hemlinger G, Netti PA, Lichtenbeld HC, et al. Solid stress inhibits the growth
of multicellular tumor spheroids. Nat Biotechnol 1997;15 : 778-83
89
35. Berger G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev
Cancer 2003;3 : 401-10
36. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9 : 685-
93
37. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in
carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the
breast. Clin Cancer Res 1999 ; 5 : 1041-56
38. Understanding angiogenesis. The angiogenesis foundation 2000 ;
angio.org/understanding.contentunderstanding.nntn
39. Kamijo T, Yokose T, Hasebe T, Yonou H, Hayashi R, Ebihara S. Image
analysis of microvessel area predicts radiosensitivity in early stage laryngeal
carcinoma treated with radiotherapy. Clinical cancer research. September
2001 ; 7.p.2809-14
40. Rubio L, Burgos JS, Morera C. Morphometric study of tumor angiogenesis
as a new prognostic factor in nasopharyngeal carcinoma patients. Pathology
oncology research. July 2000; vol 6 : p.210-16
41. Cox ME, et al. Acquisition of neuroendocrine characteristics by prostate
tumour cells is reversible : implications for prostate cancer progression.
Cancer Res, 1999;59(15) : 3821-30
42. Borre, M., B. Nerstrom, and J. Overgaard, Association between
immunohistochemical expression of vascular endothelial growth factor
(VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and
outcome in prostate cancer patients subjected to watchful waiting. Clin
Cancer Res, 2000;6(5) : 1882-90
43. Folkman, J., Fundamental concepts of the angiogenic process. Curr Mol
Med, 2003. 3(7): p. 643-51
44. Nagy, J.A., A.M. Dvorak, and H.F. Dvorak, VEGF-A(164/165) and PlGF:
roles in angiogenesis and arteriogenesis. Trends Cardiovasc Med, 2003.
13(5): p. 169-70
90
45. Shigeno, K., et al., Transrectal colour Doppler ultrasonography for
quantifying angiogenesis in prostate cancer. BJU Int, 2003. 91(3): p. 223-6
46. Strohmeyer, D., et al., Vascular endothelial growth factor and its correlation
with angiogenesis and p53 expression in prostate cancer. Prostate, 2000.
45(3): p.216-24
47. Okada, K., et al., Immunohistochemical localization of platelet-derived
endothelial cell growth factor expression and its relation to angiogenesis in
prostate. Urology, 2001. 57(2): p. 376-81
48. Kikuno, N., et al., The role of thymidine phosphorylase (TP) mRNA
expression in angiogenesis of prostate cancer. Anticancer Res, 2003.
23(2B): p. 1305-12
49. Kataoka, A., et al., Expression of thymidine phosphorylase correlates with
microvessel density in prostate cancer. Oncol Rep, 2005. 13(4): p. 597-600
50. Ren B, et al., Regulation of tumor angiogenesis by thrombospondin-
1.Biochim Biophys Acta, 2005
51. Mehta R, et al., Independent association of angiogenesis index with outcome
in prostate cancer. Clin Cancer Res, 2001. 7(1): p. 81-8
52. Grossfeld, G.D., et al., Thrombospondin-1 expression in patients with
pathologic stage T3 prostate cancer undergoing radical
prostatectomy:association with p53 alterations, tumor angiogenesis, and
tumor progression. Urology, 2002. 59(1): p. 97-102
53. Murphy, C., et al., Nonapical and cytoplasmic expression of interleukin-8,
CXCR1, and CXCR2 correlates with cell proliferation and microvessel
density in prostate cancer. Clin Cancer Res, 2005. 11(11): p. 4117-27
54. Matsuhima, H., et al., Correlation between proliferation, apoptosis, and
angiogenesis in prostate carcinoma and their relation to androgen
ablation.Cancer, 1999. 85(8):p.1822-7
55. Kosasih, E. N. dan Kosasih, A. S.2008.Tafsiran Hasil Pemeriksaan
Laboratorium Klinik. Edisi ke-2. 58, 86
91
56. Isbister, James P. dan Pittiglio, D.Harmening, alih bahasa Devy H. Ronaldi.
1999. Hematologi Klinik: pendekatan berorientasi masalah. Jakarta:
Hipokates. 4
57. Depkes RI. 1989. Hematologi. Jakarta: Pusat Pendidikan Tenaga Kerja. 1, 8,
14-5, 24-5, 27
58. Haanen, C.,Wenegar. 1980. Pengantar Ilmu Penyakit Darah. cetakan pertama.
Bandung: Binacipta.3,23
59. Widmann, FK. 1989. Tinjauan Klinis atas Hasil Pemeriksaan Laboratorium.
Edisi ke-9, Jakarta: EGC. 17-19
60. Ikatan Ahli Urologi Indonesia. Pedoman Penatalaksanaan BPH di Indonesia.
Downloaded from : http://www.iaui.or.id/ast/file/bph.pdf
61. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept
of 5 α reductase inhibition in human benign prostatic hyperplasia. Eur Urol
2000: 37:367- 80
62. Steers WD. 5α reductase activity in the prostate. Urology 2001 : 58 (Suppl
6A) :17-24
63. Anderson JB, Roehrborn CG, Schalken JSA, et al. The progression of benign
prostatic hyperplasia:examining the evidence and determining the risk. Eur
Urol 2001; 39:390-9
64. Kaplan SA. 5 α reductase inhibitors:what role study the play?Urology 2001;
(Suppl6 A) : 65-70
65. Cilotti A, Danza G, Serio M. Clinical application of 5 α reductase inhibitors.
J Endrocrinal Invest 2001; 24:199-203
66. Meidan VM, Touitou E. Treatments for androgenic alopecia and alopecia
areata:current options and future prospects. Drugs 2001; 61:53-69
67. Proscar (Finasteride) Prescribing Information, Merck & Co, Inc
68. Avodart (Dutasteride) Precribing Information, Glaxo Smith Kline
69. Wilde MI, Goa KL. Finasteride. An update of its use in the management
ofsymptomatic be nign prostatic hyperplasia. Drugs 1999; 57:557-81
70. Saez C, Gonzales-Baena AC, Japon MA, Giraldez J, Segura DI, Rodriguez-
Vallejo JM, Gonzalez-Esteban J, Miranda G, Torrubia F. Expression of basic
92
fibroblast growth factor and its receptors FGFR1 dan FGFR2 in human
benign prostatic hyperplasia treated with finasteride. The Prostate. 1999 Jul
; 40(2):83-8
71. Chapple CR. Pharmacological therapy of benign prostatic/lower urinary
tract symptoms : an overview for the practicing clinician. BJU Int 2004 vol
94 : 738-44
72. Haggstrom S, Lissbrant IF, Bergh A, Damber J. Testosterone induces
vascular endothelial growth factor synthesis in the ventral prostate in
castrated rats, J Urol, 1999, 161 : 1620-25
73. Puchner PJ, Miller MI,. The effects of finasteride on haematuria associated
with benign prostatic hyperplasia : A preliminary report, J Urol, 1995, 154 :
1779-82
74. Sieber PR, Rommel FM, Huffnagle HW, et al. The treatment of gross
hematuria secondary to prostatic bleeding with finasteride, J Urol, 1998, 159
: 1232-3
75. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen M, Burchardt T, et
al.Castration induces acute vasoconstriction of blood vessels in the rat
prostate concomitant with reduction of prostatic nitric oxide synthase
activity, J Urol, 1999, 162 : 1527-31
76. Schwarz S, Obermuller-Jevic C Ute, Hellmis Eva, Koch Winfried, Jacobi
Gunther, Biesalaskin Hans-Konrad. Lycopene Inhibits Disease Progression
in Patient with Benign Prostate Hyperplasia. J Nut,2008,138:53-49
77. Rao AV, Agarwal S. Role of Antioxidant Lycopene in Cancer and Heart
Disease. American College of Nutrition. 2002;Vol.19:5;569-3
78. Storey ML, Forshee RA, Anderson PA, Hein GL. The Relationship Between
Consumption of Tomato Products, Which Contain Lycopene, and Reduction
Risk of Prostate Cancer. Center for food and Nutritional polic. 2003;pp:70-1
79. Basu A, Imrhan V. Tomatoes Versus Lycopene in Oxodative Stress and
Carcinogenesis: Conclusion From Clinical Trials. European journal of
Clinical Nutrition.2006;pp:9-1
93
80. Agarwal S, Rao AV. Tomato Lycopene and its Role in Human Health and
Chronic Disease. CMAJ.2000;162(3):739-44
81. Meln JR, Lian F, Wang XD. Biological Activity of Lycopene
Metabolites:implication for Cancer Prevention. Nutrition
Review.2006;66:683-667
82. Bowen, Phyllis E. Selection of Surrogate Endpoint Boinmarker to Evaluate
the Efficacy of Lycopene/Tomatoes for Prevention/Progression of Prostate
Cancer. J Nut.2005;135:2068-1070
83. Barber J, Barber NJ. Lycopene and Prostate Cancer. Prostate Cancer and
Prostatic Disease.2002;5:12-6
84. Clinton S. K. 1998. Lycopene: Chemistry, biology and implication for
Human health and the disease. Nutr. Rev. 56:35
85. McCance L. Kathryn, Huether. E Sue. The Biology Basic for Disease in
Adults and Children. 2014
86. Ono M, Takeshima M, Nakano S. Mechanism of the Anticancer Effect of
Lycopene (Tetraterpenoids). The Enzymes. Volume 37;2015:p.146-7
87. Mein J.R, Lian F, Wang X.D. Biological activity of lycopene metabolites:
implica-tions for cancer prevention, Nutr. Rev. 66 (12) (2008) 667–83
88. C.H. Heldin, Targeting the PDGF signaling pathway in tumor treatment, Cell
Commun. Signal. 11 (2013) 97
89. W. Li, et al., Mechanism of human dermal fibroblast migration driven by type
I collagen and platelet-derived growth factor-BB, Mol. Biol. Cell 15 (1)
(2004) 294–309
90. Obermuller-Jevic, U. C., E. Olano-Martin, A. M.Corbacho, et al. Lycopene
inhibits the growth of normal human prostate epithelial cellsin vitro. J. Nutr.
2003;133:3356–60
91. Nahum, A., Hirsch, K., Danilenko, M., Watts, C.K., Prall, O. W., Levy, J. &
Sharoni, Y. Lycopene inhibition of cell cycle progression in breast and
endometrial cancer cells is associated with reduction in cyclin D levels and
94
retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene. 2001;20:
3428–36
92. Foster, J.S., D.C. Henley, S. Ahamed, J.Wimalasena. Esterogen and Cell
Cycle Regulation in Breast Cancer. Trend in Endocrinology and Metabolism.
2001;12 (7): 320-7
93. Febriansah R, Indriyani L, Palupi KD, Ikawati M. TOMAT (Solanum
lycopersicumL.) SEBAGAI AGEN KEMOPREVENTIF POTENSIAL.
2008. URL: https://www.researchgate.net/publication/237534133
94. Walsh PC, Retik AB. Transurethral Surgery. In : Walsh PC, Retik AB,
Vaughan ED Jr, Wein A (Eds); Campbell’s Urology 7th Ed. WB Saunders.
Philadelphia, 1998:1511-28
95. Paetau I, Khachik F, Brown ED, et al. Chronic ingestion of lycopene-rich
tomato juice or lycopene supplements significantly increases plasma
concentrations of lycopene and related tomato carotenoids in humans. Am J
Clin Nutr. 1998;68(6):1187-1195
96. Paetau I, Rao D, Wiley ER, Brown ED, Clevidence BA. Carotenoids in
human buccal mucosa cells after 4 wk of supplementation with tomato juice
or lycopene supplements. Am J Clin Nutr. 1999;70(4):490-494
97. Kucuk O, Sakar FH, Sakr W, et al. Phase II randomized clinical trial of
lycopene supplementation before radical prostatectomy. Cancer Epidermiol
Biomarkers Prev. 2001;10(8):861-868
98. Corridan BM, O’Donoghue M, Hughes DA, Morrissey PA. Low-dose
supplementation with lycopene or beta-carotene does not enhance cell-
mediated immunity in healthy free-living elderly humans. Eur J Clin Nutr.
2001;55(8):627-635
99. Wright AJ, Hughes DA, Bailey AL, Southon S. Beta-carotene and lycopene,
but not lutein, supplementation changes the plasma fatty acid profile of
healthy male non-smokers. J Lab Clin Med. 1999;134(6):592-598
95
100. Rao AV, Agarwal S. Effect of diet and smoking on serum lycopene and lipid
peroxidation. Nutr Res 1998a;18(4):713-21.
101. Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart
disease. J Am Coll Nutr 2000;19(5):563-9.
96
Lampiran 1. Tabulasi Data Penelitian
97
Lampiran 2. Dokumentasi Penelitian
Reagen Pewarnaan
Reagen antibody CD 34
Operasi TURP
98
Pengecatan Imunohistokimia CD 34 Pengecatan
Imunohistokimia CD 34
99
Lampiran 3. Hasil Pengecatan Imunohistokimia MVD (CD34)
Kelompok Kontrol (K)
Kelompok Perlakuan (P)
100
Lampiran 5. Ethical Clearance
101
Lampiran 6. Surat Izin Penelitian RSUP Dr. Kariadi Semarang